GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006 -Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006...

After the close, GW Pharma (NASDAQ: GWPH) issued two press releases and hosted a conference call to review its FY18-Q1 ending 12/31/17. The company reported that the European Medicines...